Skip to main content
Top
Published in: BMC Geriatrics 1/2017

Open Access 01-12-2017 | Research Article

An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents

Authors: Daniela C. Moga, Qishan Wu, Pratik Doshi, Amie J. Goodin

Published in: BMC Geriatrics | Issue 1/2017

Login to get access

Abstract

Background

To examine factors predicting type of bladder antimuscarinics (BAM) initiated in nursing home (NH) residents.

Methods

Incident BAM initiators following NH admission were identified by constructing a retrospective cohort from Medicare files and Minimum Data Set (MDS). Participants included all residents 65 years and older admitted in Medicare-certified NH between January 1, 2007 and December 31, 2008 who were prescribed BAM and had continuous Medicare (Part A, B, and D) enrollment. Patient characteristics, medications, and comorbidities were derived from Medicare enrollment and claims. NH characteristics and health status were derived from MDS assessments. The outcome was defined as type of BAM initiated after admission (selective, non-selective extended release, non-selective immediate release). Multinomial logistic regression using generalized estimating equation methodology determined which factors predicted the type of BAM initiated.

Results

Twelve thousand eight hundred ninety-nine NH residents initiating BAM therapy were identified; 13.38% of new users were prescribed selective BAM, 45.56% non-selective extended release, and 41.07% non-selective immediate release medications. In both sexes, significant predictors of BAM included region of nursing home, body mass index, cognitive performance score, frailty measures, activities of daily living, and measures of bladder continence. In women, history of fracture and fall-related injuries were significant predictors of type of BAM use, while race and indicators of balance were significant predictors of type of BAM use in men. Non-pharmacological continence management strategies were not predictive of type of BAM initiation.

Conclusions

Several factors are important in predicting type of BAM initiation in both women and men, but other factors are sex-specific. Some observed factors predicting the type of BAM initiated, such as other medications use, body mass index, or provider-related factors are potentially modifiable and could be used in targeted interventions to help optimize BAM use in this population.

Trial registration

Not applicable.
Appendix
Available only for authorised users
Literature
1.
go back to reference Abrams P, et al. The standardization of terminology of lower urinary function: report from the standardization sub-committee of the international continence society. Neurol Urodyn. 2002;21:167–78.CrossRef Abrams P, et al. The standardization of terminology of lower urinary function: report from the standardization sub-committee of the international continence society. Neurol Urodyn. 2002;21:167–78.CrossRef
2.
go back to reference Coyne KS, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–40.PubMed Coyne KS, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–40.PubMed
3.
go back to reference Offermans MP, et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol Urodyn. 2009;28(4):288–94.CrossRefPubMed Offermans MP, et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol Urodyn. 2009;28(4):288–94.CrossRefPubMed
4.
go back to reference Charalambous S, Trantafylidis A. Impact of urinary incontinence on quality of life. Pelviperineology. 2009;28:51–5. Charalambous S, Trantafylidis A. Impact of urinary incontinence on quality of life. Pelviperineology. 2009;28:51–5.
5.
go back to reference Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367–74.CrossRefPubMed Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367–74.CrossRefPubMed
6.
go back to reference Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc. 2006;54(9):1325–33.CrossRefPubMed Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc. 2006;54(9):1325–33.CrossRefPubMed
7.
go back to reference Wilson L, et al. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98(3):398–406.PubMed Wilson L, et al. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98(3):398–406.PubMed
8.
go back to reference Ganz ML, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32. 532.e1-18CrossRefPubMed Ganz ML, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32. 532.e1-18CrossRefPubMed
9.
go back to reference Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. 2006;119(3 Suppl 1):29–36.CrossRefPubMed Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. 2006;119(3 Suppl 1):29–36.CrossRefPubMed
10.
11.
go back to reference McFall S, et al. Evaluation and treatment of urinary incontinence. Report of a physician survey. Arch Fam Med. 1997;6(2):114–9.CrossRefPubMed McFall S, et al. Evaluation and treatment of urinary incontinence. Report of a physician survey. Arch Fam Med. 1997;6(2):114–9.CrossRefPubMed
12.
go back to reference Gormley EA, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.CrossRefPubMed Gormley EA, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.CrossRefPubMed
13.
go back to reference Goode PS, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA. 2011;305(2):151–9.CrossRefPubMedPubMedCentral Goode PS, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA. 2011;305(2):151–9.CrossRefPubMedPubMedCentral
15.
go back to reference Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 1999;64(6–7):419.CrossRefPubMed Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 1999;64(6–7):419.CrossRefPubMed
17.
go back to reference Ouslander JG, et al. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc. 2001;2(5):207–14.CrossRefPubMed Ouslander JG, et al. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc. 2001;2(5):207–14.CrossRefPubMed
18.
go back to reference Drutz HP, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(5):283–9.CrossRefPubMed Drutz HP, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(5):283–9.CrossRefPubMed
19.
go back to reference Malone Lee J, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol. 2001;165(5):1452–6.CrossRefPubMed Malone Lee J, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol. 2001;165(5):1452–6.CrossRefPubMed
20.
go back to reference Diokno A, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687–95.CrossRefPubMed Diokno A, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687–95.CrossRefPubMed
21.
go back to reference Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14–24.CrossRefPubMed Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14–24.CrossRefPubMed
22.
go back to reference Chapple C, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23(10):2347–58.CrossRefPubMed Chapple C, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23(10):2347–58.CrossRefPubMed
23.
go back to reference Lackner TE, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862–70.CrossRefPubMed Lackner TE, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862–70.CrossRefPubMed
24.
go back to reference Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006;26(3):219.CrossRefPubMed Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006;26(3):219.CrossRefPubMed
25.
go back to reference Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8):931–7.CrossRefPubMed Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8):931–7.CrossRefPubMed
26.
go back to reference Wagg A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.CrossRefPubMed Wagg A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.CrossRefPubMed
27.
go back to reference Kay G, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–201.CrossRefPubMed Kay G, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–201.CrossRefPubMed
28.
go back to reference Rudolph J, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–13.CrossRefPubMed Rudolph J, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–13.CrossRefPubMed
30.
go back to reference Narayanan S, et al. Is drug therapy for urinary incontinence used optimally in long-term care facilities? J Am Med Dir Assoc. 2007;8(2):98–104.CrossRefPubMed Narayanan S, et al. Is drug therapy for urinary incontinence used optimally in long-term care facilities? J Am Med Dir Assoc. 2007;8(2):98–104.CrossRefPubMed
31.
go back to reference Moga DC, et al. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y). 2017;3(1):139–48. Moga DC, et al. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y). 2017;3(1):139–48.
32.
go back to reference Kay G, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317.CrossRefPubMed Kay G, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317.CrossRefPubMed
33.
go back to reference Jewart RD, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13(4):324–8.CrossRefPubMed Jewart RD, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13(4):324–8.CrossRefPubMed
34.
go back to reference Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(9):1279–86.CrossRefPubMed Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(9):1279–86.CrossRefPubMed
35.
go back to reference King-Kallimanis B, et al. Longitudinal investigation of wandering behavior in department of veterans affairs nursing home care units. Int J Geriatr Psychiatry. 2010;25:166–74.CrossRefPubMed King-Kallimanis B, et al. Longitudinal investigation of wandering behavior in department of veterans affairs nursing home care units. Int J Geriatr Psychiatry. 2010;25:166–74.CrossRefPubMed
36.
go back to reference Moga D, et al. Risks and benefits of bladder antimuscarinics among elderly residents of veterans affairs community living centers. J Am Med Dir Assoc. 2013;14(10):749–60.CrossRefPubMed Moga D, et al. Risks and benefits of bladder antimuscarinics among elderly residents of veterans affairs community living centers. J Am Med Dir Assoc. 2013;14(10):749–60.CrossRefPubMed
37.
go back to reference Andersson KE, et al. The pharmacological treatment of urinary incontinence. BJU Int. 1999;84(9):923–47.CrossRefPubMed Andersson KE, et al. The pharmacological treatment of urinary incontinence. BJU Int. 1999;84(9):923–47.CrossRefPubMed
38.
go back to reference Andersson KE, et al. Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr Opin Urol. 2009;19(4):380–94.CrossRefPubMed Andersson KE, et al. Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr Opin Urol. 2009;19(4):380–94.CrossRefPubMed
39.
go back to reference Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998;349(2–3):285–92.CrossRefPubMed Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998;349(2–3):285–92.CrossRefPubMed
41.
go back to reference Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedeberg’s Arch Pharmacol. 2002;366(2):97–103.CrossRef Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedeberg’s Arch Pharmacol. 2002;366(2):97–103.CrossRef
42.
go back to reference Klausner AP, Steers WD. Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Urol Rep. 2007;8(6):441–7.CrossRefPubMed Klausner AP, Steers WD. Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Urol Rep. 2007;8(6):441–7.CrossRefPubMed
43.
go back to reference Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]. Neurourol Urodyn. 2002;21:A445. Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]. Neurourol Urodyn. 2002;21:A445.
44.
go back to reference Nilvebrant L, et al. Tolterodine--a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997;327(2–3):195–207.CrossRefPubMed Nilvebrant L, et al. Tolterodine--a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997;327(2–3):195–207.CrossRefPubMed
45.
go back to reference Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22(12):1013–28.CrossRefPubMed Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22(12):1013–28.CrossRefPubMed
47.
go back to reference Hartmaier S, et al. The MDS cognition scale: a valid instrument fo identifying and staging nursing home residents with dementia using the minimum data set. J Am Geriatr Soc. 1994;1994(42):1173–9.CrossRef Hartmaier S, et al. The MDS cognition scale: a valid instrument fo identifying and staging nursing home residents with dementia using the minimum data set. J Am Geriatr Soc. 1994;1994(42):1173–9.CrossRef
48.
go back to reference Hirdes J, Frijters D, Teare G. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc. 2003;51(1):96–100.CrossRefPubMed Hirdes J, Frijters D, Teare G. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc. 2003;51(1):96–100.CrossRefPubMed
49.
go back to reference Mahoney F, Barthel D. Functional evaluation: the Barthel index. MD State Med J. 1965;14:61–5.PubMed Mahoney F, Barthel D. Functional evaluation: the Barthel index. MD State Med J. 1965;14:61–5.PubMed
50.
go back to reference Elixhauser A, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRefPubMed Elixhauser A, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRefPubMed
51.
go back to reference Carnahan R, et al. The Anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.CrossRefPubMed Carnahan R, et al. The Anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.CrossRefPubMed
52.
go back to reference SAS Institute Inc., SAS 9.4 Help and Documentation, Cary, NC: SAS Institute Inc.; 2013. SAS Institute Inc., SAS 9.4 Help and Documentation, Cary, NC: SAS Institute Inc.; 2013.
53.
go back to reference Huybrechts K, et al. Variation in antipsychotic treatment choices across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11–7.CrossRefPubMed Huybrechts K, et al. Variation in antipsychotic treatment choices across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11–7.CrossRefPubMed
54.
go back to reference Smith DB, Feng Z, Fennell ML, Zinn JS, Mor V. Separate and unequal: racial segregation and disparities in quality across US nursing homes. Health Aff. 2007;26(5):1448–58.CrossRef Smith DB, Feng Z, Fennell ML, Zinn JS, Mor V. Separate and unequal: racial segregation and disparities in quality across US nursing homes. Health Aff. 2007;26(5):1448–58.CrossRef
55.
go back to reference Svarstad BL, Mount JK, Bigelow W. Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use. Psychiatr Serv. 2001;52(5):666–72.CrossRefPubMed Svarstad BL, Mount JK, Bigelow W. Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use. Psychiatr Serv. 2001;52(5):666–72.CrossRefPubMed
56.
go back to reference Bharucha A, et al. Prevalence of behavioral symptoms: comparison of the minimum data set assessments with research instruments. J Am Med Dir Assoc. 2008;9:244–50.CrossRefPubMedPubMedCentral Bharucha A, et al. Prevalence of behavioral symptoms: comparison of the minimum data set assessments with research instruments. J Am Med Dir Assoc. 2008;9:244–50.CrossRefPubMedPubMedCentral
Metadata
Title
An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents
Authors
Daniela C. Moga
Qishan Wu
Pratik Doshi
Amie J. Goodin
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2017
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-017-0690-2

Other articles of this Issue 1/2017

BMC Geriatrics 1/2017 Go to the issue